Browse Category:

Categories

[Search within category]

Novel method for detection of O-Sulfonation sites on post-translationally modified proteins

Sulfonation of proteins and carbohydrates plays an important role in signaling, transport, and metabolism in the body. The degree to which a molecule is modified and at what positions dictates how that structure interacts within the body. UCI researchers have developed novel methods of detecting and mapping serine and threonine sulfonation of peptides and proteins.

CONTINUOUS, EFFICIENT PRODUCTION OF MEDICAL RADIOISOTOPES

The invention is a method for instantaneous and efficient extraction of radioactive isotopes with high specific activity, during continuous production at research reactors. The proposed method allows advantageous production of radioisotopes for various applications, including nuclear medicine uses (diagnostics, imaging, cancer treatments). In addition, the invention has the potential for applications related to isotopes used in thermoelectric generators (i.e. 238Pu) that power both medical devices, such as cardiac pacemakers, and deep space missions.

Reduced IP3 Signaling As A Diagnostic Tool For Autism Spectrum Disorders

The diagnosis of Autism Spectrum Disorder (ASD), and thus the development of therapies, is very challenging due to the lack of objective criteria and biomarkers. It is, however, a disease with a strong genetic component, and recent data has implicated new genes in the disease. Researchers at UC Irvine have developed a method to more reliably diagnose ASD with a laboratory test.

Improved Methods for Encapsulation, Culture, and Transplantation of Islet Cells

Diabetes is the 4th leading cause of death in the United States, with more than 3 million Americans currently suffering from Type 1 diabetes (T1D). Islet cell transplantation is a promising treatment for T1D, in which islet cells are obtained from a donor and transplanted into a T1D patient. Researchers at UCI have developed novel methods that increase viability, yield, and long-term survival of islet cells for treatment of T1D.

Hydrogel for Improved Burn Wound Healing

Background: The US spends $25B alone on wound treatment of burns. The wound treatment market is projected to grow to $18.3B in just 4 years. Current treatments have been unsuccessful in fostering proper wound healing safe from infections. Not only do they have low efficacy, but they are very expensive to produce. The most commonly used wound dressing is a hydrogel. Hydrogels reduce pain and healing time, promotes cell proliferation and collagen deposition, and is the most appropriate for burn wounds.  Brief Description: UCR researchers have developed a novel formulation that can be embedded into a hydrogel to significantly improve wound healing. Through successful conjugation of a peptide and polymer, stability and longevity have been enhanced. Their formulation induced a 3-fold increase in density of newly formed microvessels, greatly improving tissue quality.

Selective Inhibition of Activated ErbB Tyrosine Kinases

This invention identifies a novel class of ErbB targeting small molecules.

Screening Platform for Anti-influenza Drugs

In addition to their protective functions as lubricants and physical and immunologic barriers, recent work has demonstrated that mucins also provide protection from influenza virus infection by presenting decoy ligands for the virus. In airway passages, target glycans on airway cells are covered with a thick layer of mucus containing dense array of glycosylated proteins (mucins). However, most screens are either overly simplified (and therefore not representative of the natural mucin barrier) or not translatable to a high-throughput platform. Hence, the development of a useful high throughput drug screening method has been hindered by the inability to streamline the process of replicating the complex environment that airborne invaders naturally confront.

Functionally Selective Ligands for Study and Inhibition of Inflammation

Background: Due to the complexity of the complement system cascade, biological roles of many signaling receptors are unknown. Additionally, biased ligand binding to cell-bound receptors may lead to selective intracellular effector binding and ligand-specific pathway activation and function. Mechanistic knowledge forms the basis for assay development to explore pharmacology against complement-mediated inflammatory diseases.   Brief Description: A multidisciplinary team of researchers from UCR, Texas A&M, Sheffield, and Queensland have discovered the first functionally selective peptide ligands for a complement system receptor that is involved in inflammation. The peptides are functionally selective ligands of C5aR2 but not C5aR1 or C3aR, and they have been characterized in vitro and in vivo. These peptides are novel tools that can modulate the activity of the receptor in vitro and in vivo, and interrogate the function of the receptor and its implication in inflammatory diseases.

Regulating the Microbiome with Disease-Associated Genes

Background: Inflammatory Bowel Disease (IBD) is a chronic condition with substantial health and economic costs, affecting 1.3M people in the US. Currently, there is a lack of precise understanding of IBD and therefore, many are misdiagnosed or not even diagnosed at all. There is a high demand for effective and preventative therapies to reduce the burdens of IBD. Most of the time, patients have to resort to surgery which is a very expensive and invasive process. The IBD market is expected to be $9.6B in 2017 and is projected to show robust growth due to increasing IBD prevalence.   Brief Description: UCR researchers have discovered a novel gene that can be modulated to control the microbiome. It is also the first evidence of identifying a specific bacteria in a mouse model of human disease. This discovery will allow for insight into how and which human disease-associated genes are involved in modifying the microbiome to offer better therapeutic solutions in alleviating the disease.

Technology For Sustaining Pluripotency And Improved Growth Of Stem Cells In Culture

Background: Pluripotent stem cells (PSC) have tremendous potential in regenerative medicine, cell therapy, and drug/toxicant screening, and can increase our understanding of the pathogenesis and treatment of disease. The stem cell industry has accelerated annual growth projections of 20% by 2020. Overall, there is growing demand for culture media that can support rapid growth, survival, and sustain pluripotency of stem cells. Brief Description: UCR researchers have developed a novel, non-toxic biological compound that can be added to any culture medium to prevent unwanted differentiation. Compared to the standard commercial media currently used in PSC laboratories, this compound produces major improvements in cell quality, cell growth and maintenance of pluripotency during repeated passaging. Additionally, regulatory groups categorize stem cell therapy as an orphan drug, thereby allowing accelerated approval.

Synthetic Lethal Targeting Of Rho-Associated Kinase

Clear Cell Renal Cell Carcinoma (CC-RCC) is the most common form of kidney cancer in adults. Researchers at UCI have identified novel chemical compounds and methods for treating CC-RCC by targeting and killing cancerous cells without affecting healthy cells.

Inhibitors Of Ires-Mediated Protein Synthesis

The Gera group at UCLA has discovered a novel analog of a known compound with significant anti-glioblastoma potential when used in combination with mTOR inhibitors.

Methods For Promoting Oligodendrocyte Regeneration And Remyelination

Researchers at the University of California Davis have demonstrated that immature astrocytes generated from human pluripotent stems cells, promote oligodendrocyte lineage progression via TIMP-1 secretion.

A Novel Therapeutic Against HIV Using Human T Cell Immunoglobulin Mucin (TIM-3) Ligands to Modulate Immune Response

Blocking human T cell immunoglobulin and mucin domain-containing molecule 3 (TIM-3) signaling can restore functionality to defective T cells in HIV-1 infected patients. Additionally, measuring TIM-3 provides clinicians with a novel way of evaluating, staging, and monitoring the progression of HIV infections.

miRNA Therapeutic for Huntington's Disease

Huntington's disease (HD) is a neurodegenerative genetic disorder caused by the mutation of a CAG repeat within the HD gene that causes the accumulation of mHTT species. The biochemical pathways involved in HD are complex and not yet fully uncovered. As a consequence, there are currently no successful disease-modifying therapies for HD. The identification of cellular targets that impact the disease's onset and progression is critical for the development of new treatments. Researchers at UCI and University of Iowa have identified a new target and developed an miRNA therapeutic that reduces accumulation of mHTT in a mouse model of HD.

Synthesis of Lipobactins and Teixobactin Analogues – New Antimicrobial Compositions against Gram-Positive Bacteria

With the discovery of penicillin in the 1940’s, many scientists proclaimed the defeat of infectious diseases which had plagued mankind. However, the remarkable healing power of antibiotics unfortunately invited widespread and indiscriminate use of antibiotics. This misuse and overuse of antibiotics has led to the dramatic rise in antibiotic resistant bacterial strains and increased healthcare costs.

Method to Enrich for Cells Transduced with Chimeric Antigen Receptors

Researchers at UCLA have developed a method to expand chimeric antigen receptor-transduced T cells for use in immunotherapies.

HUMAN ANTIBODY TARGETING HIGHLY SPECIFIC TUMOR CELL SURFACE ANTIGEN

These novel antibodies recognize a cell surface antigen that is highly expressed and exclusive to several types of cancers, including mesothelioma, testicular cancer, endometrial cancer, and subsets of ovarian, pancreatic, and non-small cell lung cancers, thereby holding great potential to facilitate the development of novel cancer therapies. 

NOVEL CONSORTIUM OF BACTERIA FOR THE PREVENTION AND TREATMENT OF INFLAMMATORY DISEASES

This invention is a rationally designed consortium of bacteria used for the prevention and treatment of inflammatory diseases.

Methods for Disrupting HIV Latency Using Anti-HIV Latency Agents

Researchers at the University of California, Davis have developed methods for reactivating latent viral infection in peripheral blood samples of human immunodeficiency virus (HIV)-infected individuals receiving anti-retroviral therapy and for optimizing the process by including additional reactivation agents.

Deriving Human Naïve Pluripotent Stem Cells by Modifying the Hippo Pathway Using Genetic or Chemical Approaches

This invention identifies a method of generating naïve pluripotent stem cells for subsequent use in research or for regenerative medicine.

Stem Cell Treatment for Oral Inflammatory Disease and Biomarker to Predict Response

Researchers at the University of California, Davis have developed a stem cell therapy to treat chronic, oral inflammatory disease and a biomarker for predicting whether there will be a response to therapy.

Discovery of a Candidate Drug Target for Cancer Therapy

Using primary human materials, researchers at the University of California, Santa Barbara have postulated that a G-protein coupled receptor (GPCR) might be a suitable new target for antibody-drug conjugates (ADCs).

Novel Small Molecule CFTR Activators for the Treatment of Constipation

This invention identifies novel small molecule activators of CFTR (cystic fibrosis transmembrane conductance regulator) that can be developed as effective therapies to treat constipation.

Novel Small Molecule CFTR Activators For the Treatment of Dry Eye

This invention identifies novel small molecule activators of CFTR (cystic fibrosis transmembrane conductance regulator) that can be developed as effective therapies for dry eye disorders.

  • Go to Page:

These technologies are part of the UC QuickStart program.

University of California
Innovation Alliances and Services

1111 Franklin Street, 5th Floor,Oakland,CA 94607-5200 |
http://www.ucop.edu/ott/
Tel: 510.587.6000 | Fax: 510.587.6090 | UC.technologies@ucop.edu